These include increasing, to more than 5,000 full genomes per day, the capacity for its ARTIC Next Generation Sequencing.
Eurofins has launched NovaType, a SARS-CoV-2 RT-PCR assay, clinically validated for the identification of B.1.1.7 and B.1.351 variants with a short turn-around time, ideal for retesting millions of positive samples to detect if the virus is the B.1.1.7 or B.1.351 variant.
NovaType is already available as a Laboratory Developed Test in Germany and will shortly be made available to the more than 50 Eurofins laboratories worldwide testing patients for COVID-19.
NovaType is being made available to health authorities in a number of European countries for trial and potential inclusion in their monitoring programmes in response to these new variants.
The NovaType assay will also be launched as a Research Use Only kit in Europe by the end of January 2021.
As previously outlined, the Eurofins-Viracor SARS-CoV-2 RT-PCR diagnostic test, has been ranked as the most sensitive out of more than 115 kits evaluated by the FDA SARS-CoV-2 Reference Panel.
Furthermore, this RT-PCR test maintains very high sensitivity in the detection of variants such as B.1.1.7 and B.1.351.
Through Eurofins' current COVID-19 testing and clinical diagnostics activities globally and its partnerships with leading pharmaceutical and vaccine companies, the group is able to closely monitor the identification of new variants of SARS-CoV-2 and intends to add new detection capabilities to NovaType as additional variants appear.
Eurofins said its ability to produce and distribute primers and probes, and commercial PCR kits, additionally benefits the speed of development of new assays.
With over 50,000 staff across a network of more than 800 laboratories in over 50 countries, Eurofins' companies offer a portfolio of over 200,000 analytical methods.
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Zoetis announces EU approval for Portela to relieve osteoarthritis pain in cats
4basebio synthetic DNA used in Phase I/II mRNA therapy trial
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Sanofi reports data showing high-dose flu vaccine delivers superior protection for older adults
GC Biopharma granted CMO rights for Curevo Vaccine's shingles vaccine